PSIOXUS THERAPEUTICS LIMITED Patent applications |
Patent application number | Title | Published |
20130230902 | CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT - The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index. | 09-05-2013 |
20130217095 | CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT - The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index. | 08-22-2013 |
20120231524 | CHIMERIC ADENOVIRUSES FOR USE IN CANCER TREATMENT - The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index. | 09-13-2012 |
20120141409 | MULTI-VALENT ADJUVANT DISPLAY - The present invention provides an adjuvant-polymer construct comprising a polymer backbone which is covalently linked to 3 or more adjuvants, wherein the 3 or more adjuvants are each present in a pendant side chain, the adjuvants being connected to the polymer backbone either directly or via a spacer group. | 06-07-2012 |
20120095070 | PREVENTION AND TREATMENT OF SARCOPENIA - The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose. | 04-19-2012 |